A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of three fixed doses (100mg, 200mg, or 400mg) of DVS-233 SR [desvenlafaxine sustained release] in adult outpatients with major depressive disorder.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of three fixed doses (100mg, 200mg, or 400mg) of DVS-233 SR [desvenlafaxine sustained release] in adult outpatients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 16 Aug 2017 Results (n=4279) of post-hoc pooled analysis of this and other eight double blind, placebo controlled studies, published in the Journal of Clinical Psychopharmacology.
    • 25 Aug 2009 Planned patient number (480) and actual end date (Nov 2004) added as reported by ClinicalTrials.gov.
    • 11 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top